9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2022
The DOI matches its Crossref record; 104 of the 106 references it cites were found in a registry or an index.
Abstract
The American Diabetes Association (ADA) “Standards of Medical Care in Diabetes” includes the ADA’s current clinical practice recommendations and is intended to provide the components of diabetes care, general treatment goals and guidelines, and tools to evaluate quality of care. Members of the ADA Professional Practice Committee, a multidisciplinary expert committee (https://doi.org/10.2337/dc22-SPPC), are responsible for updating the Standards of Care annually, or more frequently as warranted. For a detailed description of ADA standards, statements, and reports, as well as the evidence-grading system for ADA’s clinical practice recommendations, please refer to the Standards of Care Introduction (https://doi.org/10.2337/dc22-SINT). Readers who wish to comment on the Standards of Care are invited to do so at professional.diabetes.org/SOC.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“While generally well tolerated, an increased risk of HHF was found with saxagliptin, which is re fl ected in its label, and there have been rare reports of arthralgia and hypersensitivity reactions with the DPP-4i class (16).”
In the citing paper
“Current treatment protocols propose considering weight impact when choosing diabetes treatment strategies, and GLP-1RAs have shown a notably positive therapeutic profile for overweight or obese individuals with T2DM. 78”
From Anti-inflammatory role of glucagon-like peptide 1 receptor agonists and its clinical implications (2024) · cites this paper as [78]
In the citing paper
“Currently, these guidelines recommend SGLT2is and GLP-1RAs as the preferred therapy among individuals with type 2 diabetes and comorbid ASCVD or HF, and SGLT2is among those with comorbid CKD [8, 9].”
In the citing paper
“The ADA/ EASD statement recommends that patients with T2D who have established ASCVD, CKD, or clinical heart failure be treated with an SGLT2i (or GLP-1 RA) with proven cardiovascular bene fi t as part of a glucose-lowering regimen independent of HbA1c, but with consideration of patient-speci fi c factors.”
From KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease (2022) · cites this paper as [147]
In the citing paper
“Based on evidence from large cardiovascular outcomes trials, the latest professional society guidelines continue to recommend sodium-glucose cotransporter 2 (SGLT2) inhibitors and glucagon-like peptide-1 receptor agonists (GLP-1 RAs) for patients with type 2 diabetes (T2D) and established cardiovascular disease (CVD).1,2”
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
10-year follow-up of intensive glucose control in type 2 diabetes
Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. W. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806470 · Cited by 7,751 · cited 1×
“Metformin is effective and safe, is inexpensive, and may reduce risk of cardiovascular events and death (45).”
BackgroundIntensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes
(2005) · New England Journal of Medicine · doi:10.1056/nejmoa052187 · Cited by 5,138
Davies, M. J., D’Alessio, D. A., Fradkin, J., Kernan, W. N., Mathieu, C., Mingrone, G., Rossing, P., Tsapas, A., Wexler, D. J., & Buse, J. B. (2018) · Diabetes Care · doi:10.2337/dci18-0033 · Cited by 3,518 · cited 1×
“The ADA/EASD consensus report “Management of Hyperglycemia in Type 2 Diabetes, 2018” and the 2019 update (43,44) recommend a patient-centered approach to choosing appropriate pharmacologic treatment of blood glucose.”
BackgroundRiddle (2003) · doi:10.2337/diacare.26.11.3080 · Cited by 1,479
Buse, J. B., Wexler, D. J., Tsapas, A., Rossing, P., Mingrone, G., Mathieu, C., D’Alessio, D. A., & Davies, M. J. (2020) · Diabetes Care · doi:10.2337/dci19-0066 · Cited by 1,192
Six-Month Randomized, Multicenter Trial of Closed-Loop Control in Type 1 Diabetes
Brown, S. A., Kovatchev, B. P., Raghinaru, D., Lum, J. W., Buckingham, B. A., Kudva, Y. C., Laffel, L. M., Levy, C. J., Pinsker, J. E., Wadwa, R. P., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1907863 · Cited by 1,030
Type 1 Diabetes Through the Life Span: A Position Statement of the American Diabetes Association
Chiang, J. L., Kirkman, M. S., Laffel, L. M. B., Peters, A. L., & Authors, O. B. O. T. T. 1. D. S. (2014) · Diabetes Care · doi:10.2337/dc14-1140 · Cited by 965
Effect of intensive therapy on the microvascular complications of type 1 diabetes mellitus
The Writing Team for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group (2002) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.287.19.2563 · Cited by 941
Cardiovascular and renal outcomes with efpeglenatide in type 2 diabetes
Gerstein, H. C., Sattar, N., Rosenstock, J., Ramasundarahettige, C., Pratley, R., Lopes, R. D., Lam, C. S. P., Khurmi, N. S., Heenan, L., Del Prato, S., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2108269 · Cited by 829
Holt, R. I. G., DeVries, J. H., Hess-Fischl, A., Hirsch, I. B., Kirkman, M. S., Klupa, T., Ludwig, B., Nørgaard, K., Pettus, J., Renard, E., et al. (2021) · Diabetes Care · doi:10.2337/dci21-0043 · Cited by 699
Research works printed but not linked: 2
- Peters, 2013, American Diabetes Association/JDRF Type 1 Diabetes Sourcebook
- Vaz, 2018, Effectiveness and safety of carbohydrate counting in the management of adult patients with type 1 diabetes mellitus: a systematic review and meta-analysis, Arch Endocrinol Metab, 62, 337
Cited by
Items 301–400 of 1,000
Tsai, P.-C., Chuang, W.-J., Ko, A. M., Chen, J.-S., Chiu, C., Chen, C., & Yeh, Y. (2023) · Cardiovascular Diabetology · doi:10.1186/s12933-023-01789-5 · Cited by 26
Patient Out-of-Pocket Costs for Type 2 Diabetes Medications When Aging Into Medicare
Barthold, D., Li, J., & Basu, A. (2024) · JAMA Network Open · doi:10.1001/jamanetworkopen.2024.20724 · Cited by 23
Cardiovascular risks in type 2 diabetes and the interpretation of cardiovascular outcome trials
Hinnen, D. A., & Kruger, D. F. (2019) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s188705 · Cited by 25
Diabetes, Metformin, and Lung Cancer: Retrospective Study of the Korean NHIS-HEALS Database
Kim, J., Hyun, H.-J., Choi, E.-A., Yoo, J. W., Lee, S., Jeong, N., Shen, J. J., You, H., Kim, Y.-S., & Kang, H. (2020) · Clinical Lung Cancer · doi:10.1016/j.cllc.2020.04.001 · Cited by 25
Vilsbøll, T., Lindahl, C. Ø., Nielsen, N. F., & Tikkanen, C. K. (2023) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.15031 · Cited by 22
“Hence, semaglutide may potentially have been used for cardiovascular risk reduction management irrespective of HbA1c level, as specified in current clinical guidelines.(30-32) High levels of adherence to and persistence with medications are necessary to obtain optimal management of T2D and improve glycaemic control.”
BackgroundMethodResultInfluentialAbsorption, distribution, metabolism, and excretion of tirzepatide in humans, rats, and monkeys
Martin, J. A., Czeskis, B. A., Urva, S., & Cassidy, K. C. (2024) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2024.106895 · Cited by 27
You, J. H., Song, S. O., Kang, M. J., Cho, Y. Y., Kim, S. W., Suh, S. H., Lee, S., Lee, Y., & Lee, B. (2020) · Clinical and Translational Gastroenterology · doi:10.14309/ctg.0000000000000254 · Cited by 22
Homer, A. R., Taylor, F., Dempsey, P. C., Wheeler, M. J., Sethi, P., Grace, M. S., GREEN, D. J., Cohen, N. D., Larsen, R. N., Kingwell, B. A., et al. (2021) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2021.07.001 · Cited by 23
Giusti, L., Tesi, M., Ciregia, F., Marselli, L., Zallocco, L., Suleiman, M., Luca, C. D., Guerra, S. D., Zuccarini, M., Trerotola, M., et al. (2022) · Cells · doi:10.3390/cells11152465 · Cited by 23
“Several drugs are used to treat T2D, and metformin is the most widely employed [5,6].”
BackgroundWiwattanapatapee, R., Klabklay, K., Raksajit, N., Siripruekpong, W., Leelakanok, N., & Petchsomrit, A. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e14796 · Cited by 21
Richardson, T. L., Halvorson, A. E., Hackstadt, A. J., Hung, A. M., Greevy, R. A., Grijalva, C. G., Elasy, T. A., & Roumie, C. L. (2023) · Annals of Internal Medicine · doi:10.7326/m22-2751 · Cited by 24
Smits, M. M., & Holst, J. J. (2023) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3699 · Cited by 26
“Although these cells normally produce glucagon from Gcg using prohormone convertase 2, they can switch to PC1/3 to produce small amounts of GLP ‐ 1.”
BackgroundAntidiabetic Drugs in Breast Cancer Patients
Garczorz, W., Kosowska, A., & Francuz, T. (2024) · Cancers · doi:10.3390/cancers16020299 · Cited by 23
“Due to their beneficial effects on cardiovascular risk and renal disease progression, SGLT2i are considered to be among the first-choice drugs in the treatment of DM, particularly for patients with heart failure [81].”
BackgroundAssociazione Italiana per lo Studio del Fegato (AISF), S. I. D. D. (. A. S. I. D. (. (2021) · Eating and Weight Disorders - Studies on Anorexia Bulimia and Obesity · doi:10.1007/s40519-021-01287-1 · Cited by 22
Heerspink, H. J. L., Furtado, R. H. M., Berwanger, O. B., Koch, G. G., Martínez, F. A., Mukhtar, O., Verma, S., Gasparyan, S. B., Tang, F., Windsor, S. L., et al. (2022) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.14231021 · Cited by 25
Hawley, C. E., Lauffenburger, J. C., Paik, J. M., Wexler, D. J., Kim, S. C., & Patorno, E. (2022) · Diabetes Care · doi:10.2337/dc21-1676 · Cited by 22
Baker, D. E., Walley, K., & Levien, T. L. (2023) · Hospital Pharmacy · doi:10.1177/00185787221125724 · Cited by 21
Jiao, X., Peng, P., Zhang, Q., & Shen, Y. (2023) · Clinical Drug Investigation · doi:10.1007/s40261-023-01319-x · Cited by 24
“While GLP-1RAs is favored for treating individuals with T2DM and a high risk of cardiovascular disease [47], cautious administration is essential.”
Tesfaye, H., Paik, J. M., Wexler, D. J., Carreno-Galeano, J. T., Yu, E. W.-Y., Freedman, A., Rizzo, J. F., & Patorno, E. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70200 · Cited by 25
Dichtel, L. E. (2021) · Hepatology · doi:10.1002/hep.31886 · Cited by 26
Sodium-Glucose Co-Transporter 2 Inhibitors Reduce Macular Edema in Patients with Diabetes mellitus
Tatsumi, T., Oshitari, T., Takatsuna, Y., Ishibashi, R., Koshizaka, M., Shiko, Y., Baba, T., Yokote, K., & Yamamoto, S. (2022) · Life · doi:10.3390/life12050692 · Cited by 21
“Considering that SGLT2i are drugs that according to the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) guidelines [29,30] can be used from the early stage of diabetes management, it is possible to study its effects in a larger number of cases.”
BackgroundUpdate on Hypertension Research in 2021
Mogi, M., Maruhashi, T., Higashi, Y., Masuda, T., Nagata, D., Nagai, M., Bokuda, K., Ichihara, A., Nozato, Y., Toba, A., et al. (2022) · Hypertension Research · doi:10.1038/s41440-022-00967-4 · Cited by 24
“with type 2 diabetes (T2D) and specific cardiorenal risk, independent of diabetes status or background use of metformin [120].”
BackgroundYu, D., Zou, M., Pan, Q., Song, Y., Li, M., Zhang, X., Zhou, Y., Wang, X., & Guo, L. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.951570 · Cited by 24
Rikin, S., Deccy, S., Zhang, C., Crandall, J. P., Deng, Y., & Golestaneh, L. (2022) · Journal of General Internal Medicine · doi:10.1007/s11606-022-07863-0 · Cited by 22
Sharma, A., Wood, S. J., Bell, J. S., Blasio, M. J. D., Ilomäki, J., & Ritchie, R. H. (2023) · The Lancet Regional Health - Western Pacific · doi:10.1016/j.lanwpc.2023.100692 · Cited by 23
Hu, L., Jin, X., Li, Y., Wang, H., Yang, D., Zhang, Z., He, X., Liao, J., Chen, W., & Gong, N. (2023) · Journal of Medical Internet Research · doi:10.2196/39325 · Cited by 23
“For example, the American Diabetes Association standards of medical care for people with diabetes cover multiple aspects of medication control [7], blood glucose goals [8], and the promotion of behavioral changes to improve health outcomes (including diabetes self-management education and support,…”
Ngoc, N. B., Nguyen, L., Mital, S., Bugden, S., & Nguyen, H. V. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15009 · Cited by 25
Zhang, X., & Marx, C. M. (2023) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2023.29.3.276 · Cited by 24
Use of continuous glucose monitors in low‐ and middle‐income countries: A scoping review
Bernabé‐Ortiz, A., Carrillo-Larco, R. M., Safary, E., Vetter, B., & Lazo‐Porras, M. (2023) · Diabetic Medicine · doi:10.1111/dme.15089 · Cited by 21
SGLT2 Inhibitors Are Associated With Reduced Cardiovascular Disease in Patients With Type 2 Diabetes
Wang, W., Chen, L. Y., Walker, R. F., Chow, L. S., Norby, F. L., Alonso, Á., Pankow, J. S., & Lutsey, P. L. (2023) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2023.01.023 · Cited by 24
Tang, H., Guo, J. S., Shaaban, C. E., Zheng, F., Wu, Y., Magoč, T., Hu, X., Donahoo, W. T., DeKosky, S. T., & Bian, J. (2023) · Alzheimer s & Dementia · doi:10.1002/alz.13480 · Cited by 21
Chiaranai, C., Chularee, S., Saokaew, S., Tungpunkom, P., Umnuaypornlert, A., Chaomuang, N., Doommai, N., & Nimkuntod, P. (2023) · International Journal of Nursing Studies Advances · doi:10.1016/j.ijnsa.2023.100169 · Cited by 26
Emerging role of antidiabetic drugs in cardiorenal protection
Fu, W.-J., Huo, J., Mao, Z., Pan, S.-K., Liu, D., Liu, Z., Wu, P., & Gao, Z. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1349069 · Cited by 24
Glucagon-like peptide receptor agonists and risk for depression
Tagliapietra, G. A., Cantrell, M. A., & Lund, B. C. (2024) · Primary care diabetes · doi:10.1016/j.pcd.2024.05.005 · Cited by 21
Bouchi, R., Kondo, T., Ohta, Y., Goto, A., Tanaka, D., Satoh, H., Yabe, D., Nishimura, R., Harada, N., Kamiya, H., et al. (2024) · Journal of Diabetes Investigation · doi:10.1111/jdi.14202 · Cited by 22
“Although it is recommended by the American Diabetes Association that any medication regimen be reviewed for ef fi cacy, as well as for revision, every 3 – 6 months 20 , the revision of medication regimen in a 3-month cycle is recommended in Japan.”
BackgroundAlfayez, O. M., Almutairi, A. R., Aldosari, A. A., & Yami, M. S. A. (2019) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2019.04.003 · Cited by 22
Apergi, K., Dimosthenopoulos, C., & Παπάνας, Ν. (2023) · The International Journal of Lower Extremity Wounds · doi:10.1177/15347346231153531 · Cited by 20
Kuoni, S., Steiner, R., Saleh, L., Lehmann, R., Ochsenbein‐Kölble, N., & Simões‐Wüst, A. P. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.116177 · Cited by 21
Kiuchi, M. G., Ganesan, K., Keating, J. H., Carnagarin, R., Matthews, V. B., Herat, L. Y., Goh, G. S., Adams, L. A., & Schlaich, M. P. (2021) · Clinical Research in Cardiology · doi:10.1007/s00392-021-01814-1 · Cited by 20
Fulcher, G. R., Akhtar, S., Aljaser, S., Medina, J., Mohamed, M., Nicodemus, N. A., Olsen, A. H., Singh, K. P., & Kok, A. (2022) · Advances in Therapy · doi:10.1007/s12325-022-02212-3 · Cited by 20
Polonsky, W. H., Giorgino, F., Rosenstock, J., Whitmire, K., Lew, E., Coudert, M., Alvarez, A., Nicholls, C. J., & McCrimmon, R. J. (2022) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14822 · Cited by 22
Insulin Resistance and Diabetes Mellitus in Patients with Systemic Lupus Erythematosus
García‐Carrasco, M., Pinto, C. M., Munguía‐Realpozo, P., Etchegaray‐Morales, I., Vélez-Pelcastre, S. K., Méndez‐Martínez, S., Zamora‐Ginez, I., de Lara, L. G. V., Gálvez-Romero, J. L., & Escamilla-Márquez, M. A. (2022) · Endocrine Metabolic & Immune Disorders - Drug Targets · doi:10.2174/1871530322666220908154253 · Cited by 22
Pharmacologic Treatment of Type 2 Diabetes in the U.S., Sweden, and Israel
Lyu, B., Sang, Y., Selvin, E., Chang, A. R., Alexander, G. C., Cohen, C. M., Coresh, J., Shalev, V., Chodick, G., Karasik, A., et al. (2022) · Diabetes Care · doi:10.2337/dc22-1253 · Cited by 21
Bouchi, R., Kondo, T., Ohta, Y., Goto, A., Tanaka, D., Satoh, H., Yabe, D., Nishimura, R., Harada, N., Kamiya, H., et al. (2022) · Diabetology International · doi:10.1007/s13340-022-00605-x · Cited by 23
Oktora, M. P., Yuniar, C. T., Amalia, L., Abdulah, R., Hak, E., & Denig, P. (2023) · BMC Geriatrics · doi:10.1186/s12877-022-03718-9 · Cited by 20
Kim, K., Han, K. A., Kim, T. N., Park, C., Park, J. H., Kim, S. Y., Kim, Y. H., Song, K. H., Kang, E. S., Kim, C. S., et al. (2023) · Diabetes & Metabolism · doi:10.1016/j.diabet.2023.101440 · Cited by 20
The development and benefits of metformin in various diseases
Dong, Y., Qi, Y., Jiang, H., Tian, M., Zhang, Y., Peng, C. S., Li, W.-C., Zhang, Y., Zhou, Y., Zang, Y., et al. (2023) · Frontiers of Medicine · doi:10.1007/s11684-023-0998-6 · Cited by 21
Boye, K. S., Thieu, V. T., Sapin, H., Lee, C. J., Landó, L. F., Brown, K. E., Bray, R., Wiese, R. J., Patel, H., Rodríguez, Á., et al. (2023) · Diabetes Therapy · doi:10.1007/s13300-023-01451-z · Cited by 21
“This patient-centred approach to T2D management is becoming increasingly recognised in treatment guidelines [25].”
BackgroundGonzález‐Juanatey, C., Anguita-Sánchez, M. P., Barrios, V., Nuñez-Gil, I. J., Gómez‐Doblas, J. J., García–Moll, X., Gormaz, C. L., Rollán-Gómez, M. J., Peral-Disdier, V., Martínez‐Dolz, L., et al. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12165218 · Cited by 22
Buckeridge, C., Tsamandouras, N., Carvajal‐Gonzalez, S., Brown, L. S., Hernandez‐Illas, M., & Saxena, A. R. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15643 · Cited by 20
Evolution of Myocardial Dysfunction in Asymptomatic Patients at Risk of Heart Failure
Halabi, A., Yang, H., Wright, L. M., Potter, E. L., Huynh, Q. L., Negishi, K., & Marwick, T. H. (2020) · JACC. Cardiovascular imaging · doi:10.1016/j.jcmg.2020.09.032 · Cited by 20
Visaria, J., Uzoigwe, C., Swift, C., Dang-Tan, T., Paprocki, Y., & Willey, V. J. (2021) · Clinical Therapeutics · doi:10.1016/j.clinthera.2021.03.003 · Cited by 20
Wong, C. K. H., Lau, K. T. K., Tang, E. H. M., Lee, C., Lee, C. Y. Y., Woo, Y. C., Au, I. C. H., Tan, K. C. B., & Lui, D. T. W. (2022) · Cardiovascular Diabetology · doi:10.1186/s12933-022-01520-w · Cited by 21
Giannattasio, S., Citarella, A., Trocchianesi, S., Filardi, T., Morano, S., Lenzi, A., Ferretti, E., & Crescioli, C. (2022) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2022.879522 · Cited by 20
Orozco‐Beltrán, D., Morales, C., Artola‐Menéndez, S., Brotons, C., Carrascosa, S., González, C., Baró, O., Verdugo, A. A., de Campos, K. F., Villarejo, M., et al. (2022) · JMIR Diabetes · doi:10.2196/40377 · Cited by 21
Comprehensive analysis of key m5C modification-related genes in type 2 diabetes
Song, Y., Jiang, Y. Y., Shi, L., He, C., Zhang, W., Xu, Z., Yang, M., & Xu, Y. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2022.1015879 · Cited by 19
Jabbour, S. A., Ibrahim, N. E., & Argyropoulos, C. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11206051 · Cited by 20
The interplay between bone and heart health as reflected in medication effects: A narrative review
Trost, S. U., Tesfaye, N., & Harindhanavudhi, T. (2023) · Women s Health · doi:10.1177/17455057231165549 · Cited by 20
Galindo, R. J., Moazzami, B., Scioscia, M. F., Zambrano, C., Albury, B. S., Saling, J., Vellanki, P., Pasquel, F. J., Davis, G. M., Fayfman, M., et al. (2023) · Diabetes Care · doi:10.2337/dc22-2426 · Cited by 21
Frazer, M., Swift, C., Gronroos, N. N., Sargent, A., Leszko, M., Buysman, E. K., Alvarez, S., Dunn, T. J., Noone, J. M., & Guevarra, M. (2023) · Advances in Therapy · doi:10.1007/s12325-023-02677-w · Cited by 19
“To maintain optimal glycemic control in patients with T2DM, lifestyle modifications and pharmacotherapy with oral non-insulin anti-diabetic agents (NIADs) or insulin are needed [10].”
Mesquita, L. A., Spiazzi, B. F., Piccoli, G. F., Nogara, D. A., da Natividade, G. R., Garbin, H. I., Wayerbacher, L. F., Wiercinski, V. M., Baggio, V. A., Zingano, C. P., et al. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15509 · Cited by 20
Risk factor control and cardiovascular events in patients with type 2 diabetes mellitus
Song, D. K., Hong, Y. S., Sung, Y., & Lee, H. (2024) · PLoS ONE · doi:10.1371/journal.pone.0299035 · Cited by 22
“Finally, patients with diabetes in our study might not have used newer hypoglycemic agents protective against CVD events, such as sodium-glucose cotransporter 2 inhibitors or glucagon-like peptide-1 receptor agonists [24,25].”
BackgroundGolubić, R., Kennet, J., Parker, V., Robertson, D. C., Luo, D., Hansen, L. B., Jermutus, L., Ambery, P., Ryaboshapkina, M., Surakala, M., et al. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15579 · Cited by 21
Sodium glucose co-transporter-2 inhibitor: Benefits beyond glycemic control
Baruah, M., Makkar, B. M., Ghatnatti, V., & Mandal, K. (2019) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/ijem.ijem_160_17 · Cited by 21
Lombardo, M., Padua, E., Campoli, F., Panzarino, M., Mîndrescu, V., Annino, G., Iellamo, F., & Bellia, A. (2020) · Acta Diabetologica · doi:10.1007/s00592-020-01588-4 · Cited by 21
Arshad, A., Sarween, N., & Sharif, A. (2021) · Kidney International Reports · doi:10.1016/j.ekir.2021.06.029 · Cited by 20
Bonifácio, M., Benfato, I. D., Cruz, M. D. A., de Sales, D. C., Pandolfo, I. L., Quintana, H. T., Carvalho, C. P. D. F., de Oliveira, C. A. M., & Rennó, A. C. M. (2021) · Lasers in Medical Science · doi:10.1007/s10103-021-03434-7 · Cited by 19
Impact of a clinical pharmacist on provider prescribing patterns in a primary care clinic
Wei, E. T., Gregory, P., Halpern, D. J., Felton, M., Goldstein, B. A., Yeatts, J., Shah, K. P., & Smith, B. (2021) · Journal of the American Pharmacists Association · doi:10.1016/j.japh.2021.10.007 · Cited by 22
Baek, H.-S., Park, J., Yu, J. S., Lee, J., Yang, Y., Ha, J., Lee, S., Cho, J., Lim, D., & Kim, H. (2022) · Endocrinology and Metabolism · doi:10.3803/enm.2022.1501 · Cited by 24
Addala, A., Filipp, S. L., Figg, L. E., ANEZ-ZABALA, C., Lal, R., Gurka, M. J., Haller, M. J., Maahs, D. M., & Walker, A. F. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.1066521 · Cited by 20
Examining the evidence for weight management in individuals with type 2 diabetes
Garvey, W. T., Umpierrez, G. E., Dunn, J. P., Kwan, A. Y. M., Varnado, O. J., Konig, M., & Levine, J. A. (2022) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14764 · Cited by 18
Mohamed, S. (2024) · Medicine · doi:10.1097/md.0000000000040221 · Cited by 23
Cost and Value in Contemporary Heart Failure Clinical Guidance Documents
Ostrominski, J. W., Hirji, S. A., Bhatt, A. S., Butler, J., Fiuzat, M., Fonarow, G. C., Heidenreich, P. A., Januzzi, J. L., Lam, C. S. P., Maddox, T. M., et al. (2021) · JACC Heart Failure · doi:10.1016/j.jchf.2021.08.002 · Cited by 18
Mehta, R., Billings, L. K., Liebl, A., & Vilsbøll, T. (2022) · Diabetic Medicine · doi:10.1111/dme.14901 · Cited by 20
Clinical trials and promising preclinical applications of CRISPR/Cas gene editing
Çerçi, B., Uzay, İ. A., Kara, M. K., & Dinçer, P. (2022) · Life Sciences · doi:10.1016/j.lfs.2022.121204 · Cited by 22
Manosroi, W., Danpanichkul, P., & Atthakomol, P. (2022) · Scientific Reports · doi:10.1038/s41598-022-24280-9 · Cited by 18
Yang, C., Yao, W., Ou, H., & Kuo, S. (2023) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2023.110625 · Cited by 18
Iketani, R., & Imai, S. (2023) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.b22-00710 · Cited by 18
Krishnan, A., Hadi, Y. B., Hutson, W. R., Thakkar, S. J., & Singh, S. P. (2022) · Pancreas · doi:10.1097/mpa.0000000000002197 · Cited by 19
Polonsky, W. H., Guzman, S., & Fisher, L. (2023) · Clinical Diabetes · doi:10.2337/cd22-0131 · Cited by 20
Lipska, K. J., Huang, E. S., Liu, J. Y., Parker, M. M., Laiteerapong, N., Grant, R. W., Moffet, H. H., & Karter, A. J. (2023) · Journal of the American Geriatrics Society · doi:10.1111/jgs.18565 · Cited by 21
Liao, W., Chen, Y., Gao, Q., Gan, R.-R., Li, M., Liu, Z., Liang, J., Cui, H., Ren, K., Liu, Y., et al. (2023) · Cardiovascular Diabetology · doi:10.1186/s12933-023-02061-6 · Cited by 19
“Many guidelines exist to regulate blood glucose in critically ill patients, signifying the persisting variations in stress hyperglycemia management [43–45].”
BackgroundNeeland, I. J., Arafah, A., Bourges-Sevenier, B., Dazard, J.-E., Albar, Z., Landskroner, Z., Tashtish, N., Eaton, E., Friswold, J., Porges, J., et al. (2023) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2023.100630 · Cited by 19
Imai, T., Kato, N., Kanda, N., Hashimoto, H., Yamana, H., & Hatakeyama, S. (2024) · Diabetes Therapy · doi:10.1007/s13300-024-01613-7 · Cited by 18
“Consequently, the American Diabetes Association recommends SGLT2 inhibitors as first-line medications for patients with diabetes who have these comorbidities [6].”
Bouchi, R., Kondo, T., Ohta, Y., Goto, A., Tanaka, D., Satoh, H., Yabe, D., Nishimura, R., Harada, N., Kamiya, H., et al. (2024) · Diabetology International · doi:10.1007/s13340-024-00723-8 · Cited by 21
“…Diabetes Association (ADA) have been extensively revised in 2022 to address compelling issues in diabetes management, such as diabetic comorbidities (e.g., atherosclerotic cardiovascular disease), patient-related factors in diabetes treatment, and the therapeutic needs of affected individuals [20].”
Kaur, P., Gill, H. K., Mahendru, S., & Mithal, A. (2019) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/ijem.ijem_566_18 · Cited by 22
Donnan, J. R., Johnston, K., Chibrikov, E., Marra, C. A., Aubrey‐Bassler, K., Najafzadeh, M., Nguyen, H. V., & Gamble, J. (2019) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2019.04.014 · Cited by 19
Amin, A. M. (2021) · Lifestyle Medicine · doi:10.1002/lim2.25 · Cited by 21
Management of bone fragility in type 2 diabetes: Perspective from an interdisciplinary expert panel
Chiodini, I., Gaudio, A., Palermo, A., Napoli, N., Vescini, F., Falchetti, A., Merlotti, D., Eller-Vainicher, C., Carnevale, V., Scillitani, A., et al. (2021) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2021.04.014 · Cited by 20
Safety, tolerability and pharmacokinetic characterisation of DACRA KBP‐042 in healthy male subjects
Henriksen, K., Broekhuizen, K., de Boon, W. M. I., Karsdal, M. A., Bihlet, A. R., Christiansen, C., Dillingh, M. R., de Kam, M., Kumar, R., Burggraaf, J., et al. (2021) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.14921 · Cited by 19
Effects of Sodium-Glucose Co-Transporter-2 Inhibitors on Pancreatic β-Cell Mass and Function
Nakamura, A. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23095104 · Cited by 20
Lim, L., Lau, E. S. H., Cheung, J. T. K., Chan, S. P., Ji, L., Lim, S. K., Sirinvaravong, S., Unnikrishnan, A., Luk, A. O. Y., Cortese, V., et al. (2022) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14865 · Cited by 23
Chen, W.-H., Li, Y., Yang, L., Allen, J. M., Shao, H., Donahoo, W. T., Billelo, L., Hu, X., Shenkman, E. A., Bian, J., et al. (2024) · PLOS ONE · doi:10.1371/journal.pone.0297208 · Cited by 17
Yang, L., Gabriel, N., Hernandez, I., Winterstein, A. G., & Guo, J. (2021) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.5206 · Cited by 17
Varin, E. M., McLean, B. A., & Lovshin, J. A. (2019) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2019.08.011 · Cited by 19
Kupai, K., Várkonyi, T. T., Török, S., Gáti, V., Czimmerer, Z., Puskás, L. G., & Szebeni, G. J. (2022) · Life · doi:10.3390/life12081205 · Cited by 19
Factors Affecting Performance of Insulin Pen Injector Technology: A Narrative Review
Sparre, T., Hammershøy, L., Steensgaard, D. B., Sturis, J., Vikkelsøe, P., & Azzarello, A. (2022) · Journal of Diabetes Science and Technology · doi:10.1177/19322968221145201 · Cited by 18
Kim, S. Y., Park, S., Kim, B., Min, C., Cho, W., Yon, D. K., Kim, J. Y., Han, K.-D., Rhee, E., Lee, W., et al. (2023) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2023.110626 · Cited by 17
Oktora, M. P., de Vos, S., de Vries, S. T., Hak, E., & Denig, P. (2023) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.5672 · Cited by 17
“1,22 It is of interest whether initiation with this new drug class and subsequent treatment patterns differ between the sexes.”
BackgroundClinical Trial: Probiotics in Metformin Intolerant Patients with Type 2 Diabetes (ProGasMet)
Nabrdalik, K., Drożdż, K., Kwiendacz, H., Skonieczna‐Żydecka, K., Łoniewski, I., Kaczmarczyk, M., Wijata, A. M., Nalepa, J., Holleman, F., Nieuwdorp, M., et al. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.115650 · Cited by 22
Metadata
- Authors
- American Diabetes Association Professional Practice Committee
- Corresponding author
- American Diabetes Association Professional Practice Committee
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2021-12-16
- Volume
- 45
- Issue
- Supplement_1
- Pages
- S125-S143
- ISSN
- 0149-5992 (ISSN-L)
- OpenAlex
- W4200161106
- Cited by
- 1,555
- References
- 106
- Citations by year
- 2026: 42 · 2025: 132 · 2024: 219 · 2023: 393 · 2022: 403 · 2021: 153
- FWCI
- 44.86
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Diabetes Care (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Education
- Keywords
- glycemic control, pharmacotherapy, antidiabetic drugs, treatment goals, quality of care, clinical guidelines
- MeSH terms
- Blood Glucose, Diabetes Mellitus, Endocrinology, Humans, Reference Standards, Societies, Medical, Standard of Care
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.